Immature Exosomes Derived from MicroRNA-146a Overexpressing Dendritic Cells Act as Antigen-Specific Therapy for Myasthenia Gravis

Immature Exosomes Derived from MicroRNA-146a Overexpressing Dendritic Cells Act as Antigen-Specific Therapy for Myasthenia Gravis
复制标题

过表达 MicroRNA-146a 的树突状细胞衍生的未成熟外泌体可作为重症肌无力的抗原特异性疗法

DOI:
10.1007/s10753-017-0589-2
复制
发表时间:
2017-05
期刊:
影响因子:
5.1
通讯作者:
Yang Huan
Yang Huan
中科院分区:
医学2区
文献类型:
--
作者:
Yin Weifan;Ouyang Song;Luo Zhaohui;Zeng Qiuming;Hu Bo;Xu Liqun;Li Yuan;Xiao Bo;Yang Huan

文献摘要

参考文献

相似文献

重症肌无力(MG)是一种神经系统自身免疫性疾病,其特征是某些随意肌的波动性无力。目前MG的治疗主要是通过使用免疫抑制剂或糖皮质激素来抑制整个免疫系统,并且通常会引起一些副作用。MG的理想治疗方法应该是特异性抑制异常的免疫激活,同时保持免疫系统的正常功能。在这项研究中,我们首先从过表达microRNA-146 a的树突状细胞(DC)中产生外泌体。然后,我们观察了这些exosomes在实验性自身免疫性重症肌无力(EAMG)小鼠中的抑制作用。结果显示,来自microRNA-146 a过表达DC的外泌体表达降低水平的CD 80和CD 86。在实验性自身免疫性MG中,来自microRNA-146 a过表达DC的外泌体抑制小鼠中正在进行的临床MG,并改变血清和脾脏中的Th 1/Th 17至Th 2/Treg的辅助性T细胞谱,并且这些外泌体的治疗效果是抗原特异性的,部分剂量依赖性的。为MG的抗原特异性治疗提供了实验依据。
Myasthenia gravis (MG) is a neurological autoimmune disease characterized by fluctuating weakness of certain voluntary muscles. Current treatments for MG are largely directed at suppressing the whole immune system by using immunosuppressants or glucocorticoids and often cause several side effects. The ideal therapeutic methods for MG should suppress aberrant immunoactivation specifically, while retaining normal function of the immune system. In this study, we first produced exosomes from microRNA-146a overexpressing dendritic cells (DCs). Then, we observed suppressive effects of those exosomes in experimental autoimmune myasthenia gravis (EAMG) mice. Results showed that exosomes from microRNA-146a overexpressing DCs expressed decreased levels of CD80 and CD86. In experimental autoimmune MG, exosomes from microRNA-146a overexpressing DCs suppressed ongoing clinical MG in mice and altered T helper cell profiles from Th1/Th17 to Th2/Treg both in serum and spleen, and the therapeutic effects of those exosomes were antigen-specific and partly dose dependent. All the findings provide experimental basis for antigen-specific therapy of MG.
DOI: 10.1016/j.ymthe.2005.09.015
发表时间: 2006-02-01
期刊: MOLECULAR THERAPY
影响因子: 12.4
作者:
Kim, SH;Bianco, N;Robbins, PD
通讯作者: Robbins, PD
DOI: 10.4049/jimmunol.1401392
发表时间: 2014-11-15
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者:
Luo J;Lindstrom J
通讯作者: Lindstrom J
DOI: --
发表时间: 1987
影响因子: 4.6
作者:
A. Rødgaard;F. Nielsen;R. Djurup;F. Somnier;S. Gammeltoft
通讯作者: A. Rødgaard;F. Nielsen;R. Djurup;F. Somnier;S. Gammeltoft
DOI: 10.1056/nejm196202152660703
发表时间: 1962-02
期刊: The New England Journal of Medicine
影响因子: --
作者:
D. Drachman
通讯作者: D. Drachman
DOI: 10.1016/j.molimm.2011.04.021
发表时间: 2011-09
影响因子: 3.6
作者:
K. Doffek;Xiao Chen;S. Sugg;J. Shilyansky
通讯作者: K. Doffek;Xiao Chen;S. Sugg;J. Shilyansky